Cargando…

Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2–3 trial

BACKGROUND: Peri-operative chemotherapy and surgery is a standard of care for patients with resectable oesophagogastric adenocarcinoma. Bevacizumab, a monoclonal antibody against VEGF, improves the proportion of patients responding to treatment in advanced gastric cancer. We aimed to assess the safe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cunningham, David, Stenning, Sally P, Smyth, Elizabeth C, Okines, Alicia F, Allum, William H, Rowley, Sam, Stevenson, Laura, Grabsch, Heike I, Alderson, Derek, Crosby, Thomas, Griffin, S Michael, Mansoor, Wasat, Coxon, Fareeda Y, Falk, Stephen J, Darby, Suzanne, Sumpter, Kate A, Blazeby, Jane M, Langley, Ruth E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lancet Pub. Group 2017
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5337626/ https://www.ncbi.nlm.nih.gov/pubmed/28163000 http://dx.doi.org/10.1016/S1470-2045(17)30043-8

Ejemplares similares

Quality assurance of surgery in the randomized ST03 trial of perioperative chemotherapy in carcinoma of the stomach and gastro‐oesophageal junction
por: Allum, W. H., et al.
Publicado: (2019)

Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial
por: Waddell, Tom, et al.
Publicado: (2013)

Safety and Efficacy of the Addition of Lapatinib to Perioperative Chemotherapy for Resectable HER2-Positive Gastroesophageal Adenocarcinoma: A Randomized Phase 2 Clinical Trial
por: Smyth, Elizabeth C., et al.
Publicado: (2019)

Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trial
por: Alderson, Derek, et al.
Publicado: (2017)

Effect of Pathologic Tumor Response and Nodal Status on Survival in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy Trial
por: Smyth, Elizabeth C., et al.
Publicado: (2016)

Early recognition of anorexia through patient-generated assessment predicts survival in patients with oesophagogastric cancer
por: Abraham, Marc, et al.
Publicado: (2019)

Characterising timing and pattern of relapse following surgery for localised oesophagogastric adenocarcinoma: a retrospective study
por: Moorcraft, Sing Yu, et al.
Publicado: (2016)

Relative Prognostic Value of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Operable Oesophagogastric Cancer
por: Chan, David S. Y., et al.
Publicado: (2012)

DOCUMENT REPOSITORY OPERATIONAL & PUBLICATIONS DATABASE OPERATIONAL: MILESTONES: MS03 & MS04
por: Brandt, C., et al.
Publicado: (2011)

Impact of postoperative chemotherapy on survival for oesophagogastric adenocarcinoma after preoperative chemotherapy and surgery
por: Rahman, Saqib, et al.
Publicado: (2021)

Council Resolution concerning the Operation of LEP in the Year 2000
Publicado: (1997)

Identifying outcomes reported in exercise interventions in oesophagogastric cancer survivors: a systematic review
por: O’Connor, Louise, et al.
Publicado: (2021)

The evolving immunotherapeutic landscape in advanced oesophagogastric cancer
por: Flynn, Michael, et al.
Publicado: (2018)

A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. The Medical Research Council Brain Tumour Working Party.
por: Bleehen, N. M., et al.
Publicado: (1991)

A population-based observational study on the factors associated with the completion of palliative chemotherapy among patients with oesophagogastric cancer
por: Groene, Oliver, et al.
Publicado: (2015)

Perioperative Therapy of Oesophagogastric Adenocarcinoma: Mainstay and Future Directions
por: Bose, Katrin, et al.
Publicado: (2017)

Booster Operation Committee: Minutes of the 48th meeting (15.03.1978)
por: Dekkers, D, et al.
Publicado: (1978)

Council Decisions with Regard to the End of the Period of Construction and Bringing into Operation of the SPS
Publicado: (1978)

Council Decisions with Regard to the End of the Period of Construction and Bringing into Operation of the SPS
Publicado: (1978)

Effect of perioperative FLOT versus ECF/ECX on short-term outcomes after surgery for resectable oesophagogastric adenocarcinoma: propensity score-matched study
por: Moussa, Osama, et al.
Publicado: (2022)

Laparoscopic fundoplication and new aspects of neural anatomy at the oesophagogastric junction
por: Gehwolf, P., et al.
Publicado: (2020)

Laparoscopic vs. open feeding jejunostomy insertion in oesophagogastric cancer
por: Mastoridis, Sotiris, et al.
Publicado: (2021)

Genomic loss of heterozygosity and survival in the REAL3 trial
por: Smyth, Elizabeth C., et al.
Publicado: (2018)

Medical Research Council: Investigations on Respiratory Dust Disease in Operatives in the Cotton Industry
Publicado: (1936)

Opération du PS - Expériences de physique: Opération du PS no. 119 - période du 10.2 au 27.03.1986
por: Henny, L, et al.
Publicado: (1986)

Successful Operation for the Removal of the Superior Maxillary and Malar Bones
por: Crosby, Dixi
Publicado: (1859)

The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy
por: Jimenez-Fonseca, Paula, et al.
Publicado: (2023)

Cardiopulmonary exercise testing as a predictor of complications in oesophagogastric cancer surgery
por: Moyes, LH, et al.
Publicado: (2013)

Prognostic value of histopathological regression in 850 neoadjuvantly treated oesophagogastric adenocarcinomas
por: Schmidt, T, et al.
Publicado: (2014)

Assessment of a Noninvasive Exhaled Breath Test for the Diagnosis of Oesophagogastric Cancer
por: Markar, Sheraz R., et al.
Publicado: (2018)

The Development, Application and Analysis of an Enhanced Recovery Programme for Major Oesophagogastric Resection
por: Underwood, Timothy J., et al.
Publicado: (2017)

The Effect of COVID-19 on Multidisciplinary Team (MDT) Outcomes for Oesophagogastric Cancer
por: Matias, Nadia, et al.
Publicado: (2023)

Reduced genomic tumor heterogeneity after neoadjuvant chemotherapy is related to favorable outcome in patients with esophageal adenocarcinoma
por: Obulkasim, Askar, et al.
Publicado: (2016)

Prognostic value of pathological lymph node status and primary tumour regression grading following neoadjuvant chemotherapy – results from the MRC OE02 oesophageal cancer trial
por: Davarzani, Nasser, et al.
Publicado: (2018)

Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF
por: Sumpter, K, et al.
Publicado: (2005)

Biopsy proportion of tumour predicts pathological tumour response and benefit from chemotherapy in resectable oesophageal carcinoma: results from the UK MRC OE02 trial
por: Hale, Matthew D., et al.
Publicado: (2016)

Trends and variation in the management of oesophagogastric cancer patients: a population-based survey
por: Lyratzopoulos, Georgios, et al.
Publicado: (2009)

The role of the Shuttle Walking Test in predicting mortality and morbidity post oesophagogastric surgery
por: Whiting, P, et al.
Publicado: (2005)

Failure to rescue patients from early critical complications of oesophagogastric cancer surgery
por: Weledji, Elroy P., et al.
Publicado: (2016)

Endoluminal Vacuum Therapy (E-Vac): A Treatment Option in Oesophagogastric Surgery
por: Pournaras, D. J., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_dnev8rdtlgrnbop2927qp3fmhu